This trial is active, not recruiting.

Condition removal of excess or unwanted body hair
Treatments venus versa, ipl gel
Sponsor Venus Concept
Start date January 2015
End date January 2017
Trial size 120 participants
Trial identifier NCT02452398, CS0115


This is a Multi-center, blinded, baseline-controlled, prospective study to evaluate permanent hair reduction and removal for skin types V and VI using IPL.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Hair removal treatment using Venus Versa IPL energy
venus versa
The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures. The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated. The applicator that will be used for this study (HR 690) has a wavelength of 690 nm and has a spot size (treatment area) of 30 mm by 10 mm.
ipl gel
water based gel used to protect the skin during light based treatments. Also used during ultrasound treatments.

Primary Outcomes

Hair Counts
time frame: Baseline (week 0)
Hair Counts
time frame: Before treatment 3 (approximately week 8)
Hair Counts
time frame: Before treatment 6 (approximately week 20)
Hair Counts
time frame: 1 month post treatment 6 (approximately week 28)
Hair Counts
time frame: 3 months post treatment 6 (approximately week 36)
Hair Counts
time frame: 6 months post treatment 6 (approximately week 48)

Secondary Outcomes

Subject satisfaction / assessment
time frame: approximately week 12
Subject satisfaction / assessment
time frame: approximately week 24
Subject satisfaction / assessment
time frame: I month post treatment 6 (approximately week 16)
Subject satisfaction / assessment
time frame: 3 months post treatment 6 (approximately week 24)
Subject satisfaction / assessment
time frame: 6 months post treatment 6 (approximately week 36)

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: 1. Able to read, understand and provide written Informed Consent; 2. Subject has black or dark brown terminal hairs in the areas to be treated. 3. Terminal hair density requirement of greater than 15 hairs within the hair count site (3x3 cm area) as determined by manual hair count performed by the study investigator. 4. Healthy adult, male or female, 21 years of age or older with skin type V-VI; 5. Having a suitable treatment area for hair removal; 6. Able and willing to comply with the treatment/follow-up schedule and requirements; 7. Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control at least three months prior to enrollment and throughout the course of the study. Exclusion Criteria: 1. Subject has light ,gray terminal or fine hairs in all/some parts of the treated area; 2. Pregnant, expectation of pregnancy, postpartum or nursing (<6 months); 3. Hormonal disorders that may affect hair growth; 4. Immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications; 5. Livedo reticularis; 6. Uncontrolled systemic diseases such as diabetes; 7. Active infections in the treated area; 8. Dysplastic nevi; 9. Significant concurrent skin conditions or any inflammatory skin conditions; 10. Active cold sores, open lacerations or abrasions; 11. Chronic or cutaneous viral, fungal, or bacterial diseases; 12. Current cancer; 13. History of skin cancer or pre-cancerous lesions at the treatment areas; 14. Use of Accutane™ (Isotretinoin) within the past six month; 15. Keloid or Hypertrophic scar formation in the treatment area; 16. Tattoos in the treatment area; 17. Bleeding coagulopathies or use of anticoagulants; 18. Auto-immune disorders; 19. Erythema abigne, when identified treatments should be discontinued; 20. Photosensitivity disorder that can be exacerbated by laser or intense light; 21. Herpes simplex in the treatment area; 22. Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light; 23. Poor wound healing; 24. Sunburns; 25. Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation; 26. Prior skin treatment with laser or other devices on the same treated areas within the last six months prior to study enrollment or during the course of the study.

Additional Information

Official title Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types V-VI Using Intense Pulsed Light
Description One hundred and twenty (120) subjects who are Fitzpatrick Skin Type V-VI, and have a suitable treatment area for hair removal will be evaluated in this study. Each subject will receive six treatments at four to six week intervals upon re-growth of hair and return for follow-up visits at one, three and six months after the last treatment. Measurement Equipment Standard High Resolution Digital Camera Labels for hair count Customized hair count sticker templates will be placed directly on the skin and the hairs in this window will be counted at specific visits during the study as detailed in section. Study Procedures Each subject will participate in the study for a period of at least 11 months. The study is anticipated to be completed within twelve months. Test spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / setting. Treatment The treatment areas are divided into 3 groups. Each Subjects will be allocated to one of the following groups:: - Two small anatomical areas (right and left axillae and double sided bikini line) or; - One double sided large area (right and left thighs) or; - One large area (whole back / abdomen) Based on the mild nature of treatment, anesthesia is not required. Before starting treatment apply a layer of conductive gel to the treatment area. After applying the conductive gel, locate the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse. In order to ensure full coverage of the treatment area applicator placement should overlap approximately 1/3 of the previously treated skin. Post-treatment Instructions Cold packs may be placed on the treated area for post treatment cooling. Subjects should be aware that post treatment erythema, edema and some discomfort of the treated areas are possible and should not be a cause for concern. They may also experience some purpura in the treated areas which would be expected to resolve within several days.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Venus Concept.